Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10065906 | 0.98 | MEN1 (0.43) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL13679069 | 0.98 | MEN1 (0.43) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL14597556 | 0.96 | MEN1 (0.41) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL29359268 | 0.93 | MEN1 (0.47) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL29283697 | 0.89 | MEN1 (0.50) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL9005388 | 0.89 | MEN1 (0.50) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL1439820 | 0.89 | MEN1 (0.50) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL9229842 | 0.89 | MEN1 (0.50) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL9005393 | 0.89 | MEN1 (0.50) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL9229835 | 0.89 | MEN1 (0.50) | MEN1THRBHTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915450-B2 | Transfection reagents | Life Technologies Corporation (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100159593-A1 | TRANSFECTION REAGENTS | Life Technologies Corporation (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100159593-A1 | TRANSFECTION REAGENTS | CPS1, PHAX, HNRNPH3 | MEN1 2613/4885THRB 449/4885HTT 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.